PLUS THERAPEUTICS Files S-1 for Continuous Offering
Ticker: PSTV · Form: S-1 · Filed: Jun 18, 2025 · CIK: 1095981
| Field | Detail |
|---|---|
| Company | Plus Therapeutics, Inc. (PSTV) |
| Form Type | S-1 |
| Filed Date | Jun 18, 2025 |
| Risk Level | medium |
| Sentiment | bearish |
Sentiment: bearish
Topics: S-1 Filing, Continuous Offering, Selling Stockholder, Biotechnology, Medical Devices, SEC Filing, Dilution Risk
Related Tickers: PSTV
TL;DR
**PSTV's S-1 is a red flag for potential dilution; existing holders are cashing out, not the company raising capital.**
AI Summary
PLUS THERAPEUTICS, INC. (PSTV) filed an S-1 registration statement on June 17, 2025, for a delayed or continuous offering of securities by a selling stockholder under Rule 415. The company, classified as a non-accelerated filer and a smaller reporting company, did not disclose specific revenue or net income figures within the provided excerpt. The filing indicates a strategic move to allow existing securities to be resold, rather than a primary offering to raise new capital. Key business changes include a shift in its principal executive offices from Austin, TX to Houston, TX, specifically 2710 Reed Road, Suite 160. The primary risk highlighted is the inherent uncertainty of a 'from time to time' offering, which could impact stock price volatility. The strategic outlook appears focused on providing liquidity for existing shareholders without immediate plans for significant capital infusion through this specific filing.
Why It Matters
This S-1 filing by PLUS THERAPEUTICS allows a selling stockholder to offer securities on a continuous basis, which could introduce downward pressure on PSTV's stock price due to increased supply without new capital infusion for company operations. For investors, it signals potential dilution or a lack of confidence from existing holders, contrasting with competitors who might be raising capital for growth. Employees and customers are less directly impacted by this specific filing, but sustained stock price weakness could affect morale or future investment. The broader market will observe how this 'from time to time' offering impacts a smaller reporting company in the surgical and medical instruments sector.
Risk Assessment
Risk Level: medium — The risk level is medium because the S-1 is for a 'delayed or continuous basis' offering by a 'selling stockholder,' not the company itself raising capital. This means existing shares could be sold into the market 'from time to time,' potentially increasing supply and putting downward pressure on PSTV's stock price without the benefit of new funds for company operations.
Analyst Insight
Investors should exercise caution and monitor the volume and timing of sales by the selling stockholder. Consider this a potential overhang on PSTV's stock price and evaluate the company's underlying fundamentals and cash burn rate before making any investment decisions.
Executive Compensation
| Name | Title | Total Compensation |
|---|---|---|
| Andrew Sims | Chief Financial Officer |
Key Numbers
- 2025-06-17 — Filing Date (Date S-1 was filed with the SEC)
- 737.255.7194 — Business Phone (Contact number for Plus Therapeutics, Inc.)
- 33-0827593 — IRS Employer Identification Number (Tax ID for Plus Therapeutics, Inc.)
Key Players & Entities
- PLUS THERAPEUTICS, INC. (company) — Registrant in S-1 filing
- Andrew Sims (person) — Chief Financial Officer of Plus Therapeutics, Inc. and agent for service
- David E. Danovitch (person) — Counsel from Sullivan & Worcester LLP
- Aaron M. Schleicher (person) — Counsel from Sullivan & Worcester LLP
- Sullivan & Worcester LLP (company) — Legal counsel for the Registrant
- Securities and Exchange Commission (regulator) — Recipient of the S-1 filing
- Rule 415 (regulator) — SEC rule governing delayed or continuous offerings
- 333-288121 (regulator) — SEC File Number for the S-1 registration statement
FAQ
What is the purpose of PLUS THERAPEUTICS' S-1 filing?
The S-1 filing by PLUS THERAPEUTICS, INC. (PSTV) on June 17, 2025, is for a delayed or continuous offering of securities by a selling stockholder under Rule 415, not to raise new capital for the company itself.
Who is the agent for service for PLUS THERAPEUTICS, INC.?
Andrew Sims, the Chief Financial Officer of Plus Therapeutics, Inc., located at 2710 Reed Road, Suite 160, Houston, Texas 77002, is listed as the agent for service.
What is the primary risk associated with this PLUS THERAPEUTICS S-1 filing?
The primary risk is potential downward pressure on PSTV's stock price due to the 'from time to time' sale of existing shares by a selling stockholder, which increases market supply without injecting new capital into the company.
Where are PLUS THERAPEUTICS' principal executive offices located?
PLUS THERAPEUTICS, INC.'s principal executive offices are located at 2710 Reed Road, Suite 160, Houston, Texas 77002, with a business phone number of (737) 255-7194.
Is PLUS THERAPEUTICS considered a large accelerated filer?
No, PLUS THERAPEUTICS, INC. is indicated as a 'non-accelerated filer' and a 'smaller reporting company' in the S-1 filing, not a large accelerated filer.
What is the SEC file number for this PLUS THERAPEUTICS S-1 registration statement?
The SEC file number for this S-1 registration statement for PLUS THERAPEUTICS, INC. is 333-288121, as filed on June 17, 2025.
Who are the legal counsels involved in this PLUS THERAPEUTICS S-1 filing?
David E. Danovitch and Aaron M. Schleicher from Sullivan & Worcester LLP, located at 1251 Avenue of the Americas, New York, New York 10020, are listed as legal counsels.
What industry does PLUS THERAPEUTICS operate in?
PLUS THERAPEUTICS, INC. operates in the 'Surgical & Medical Instruments & Apparatus' industry, as indicated by its Standard Industrial Classification (SIC) code 3841.
When was PLUS THERAPEUTICS' S-1 registration statement filed with the SEC?
The S-1 registration statement for PLUS THERAPEUTICS, INC. was filed with the Securities and Exchange Commission on June 17, 2025.
What does 'delayed or continuous basis' mean for PLUS THERAPEUTICS' offering?
For PLUS THERAPEUTICS, 'delayed or continuous basis' means the selling stockholder can offer the registered securities 'from time to time' after the registration statement becomes effective, providing flexibility in timing sales to the public.
Risk Factors
- Uncertainty of 'From Time to Time' Offering [medium — financial]: The S-1 filing indicates a delayed or continuous offering of securities by a selling stockholder under Rule 415. This 'from time to time' offering structure introduces uncertainty regarding the timing and volume of shares that may be sold, potentially leading to increased stock price volatility.
Industry Context
PLUS THERAPEUTICS, INC. operates within the surgical and medical instruments & apparatus industry (SIC 3841). This sector is characterized by innovation in medical technology, stringent regulatory oversight from bodies like the FDA, and a competitive landscape driven by research and development, intellectual property, and market access.
Regulatory Implications
As a medical device company, PLUS THERAPEUTICS, INC. is subject to rigorous regulatory scrutiny, particularly concerning product development, clinical trials, and marketing approvals. The S-1 filing itself is a regulatory requirement for public offerings, and ongoing compliance with SEC regulations is essential.
What Investors Should Do
- Monitor Selling Stockholder Activity
- Evaluate Business Fundamentals Independently
- Assess Stock Price Volatility
Key Dates
- 2025-06-17: S-1 Registration Statement Filed — Indicates the company's intention to allow for the resale of securities by a selling stockholder, rather than a primary capital raise.
- 2005-07-12: Name Change from CYTORI THERAPEUTICS, INC. — Historical information about the company's corporate identity evolution.
- 2001-03-20: Name Change from MACROPORE INC — Further historical context on the company's corporate identity changes.
Glossary
- S-1 Registration Statement
- A form filed with the U.S. Securities and Exchange Commission (SEC) by companies intending to offer securities to the public. It contains detailed information about the company's business, financial condition, and management. (This filing indicates the company's intent to allow existing securities to be resold, as opposed to raising new capital.)
- Rule 415
- A rule that permits securities to be registered for the sale on a delayed or continuous basis. This is often referred to as a 'shelf registration'. (The filing specifies that the offering is being made under Rule 415, allowing for flexibility in the timing and manner of the sale of securities by the selling stockholder.)
- Non-accelerated filer
- A filer that does not meet the thresholds for being an accelerated filer or a large accelerated filer, typically based on public float and filing history. They have fewer SEC reporting obligations. (Classifies PLUS THERAPEUTICS, INC. as a smaller company with potentially less stringent reporting requirements.)
- Smaller reporting company
- A company that meets certain criteria related to public float and annual revenues, allowing it to file simplified financial disclosures. (Indicates that PLUS THERAPEUTICS, INC. qualifies for scaled-down disclosure requirements, which may limit the depth of information available to investors.)
Year-Over-Year Comparison
This S-1 filing on June 17, 2025, is for a delayed or continuous offering by a selling stockholder under Rule 415, indicating a focus on providing liquidity rather than raising new capital. The company has also updated its principal executive offices to Houston, TX. As this is a registration statement for resale, it does not provide comparative financial metrics like revenue growth or margin changes against a prior period's operational performance. New risks highlighted relate to the inherent uncertainty and potential stock price volatility associated with 'from time to time' offerings.
Filing Details
This Form S-1 (Form S-1) was filed with the SEC on June 18, 2025 by Andrew Sims regarding PLUS THERAPEUTICS, INC. (PSTV).